Holy Grail Of Precision Medicine - Co-Development Of Therapeutics And Companion Diagnostics - Hasn’t Yet Achieved Its Potential Developing a novel biomarker test in parallel with a therapeutic - with the expectation that the biomarker test is going to be included in the FDA-approved label - is accompanied by a set of significant scientific and commercialization challenges.